NCT04604782View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myocardial IschemiaCoronary Artery Disease
Interventions
DRUG

Regadenoson

Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR

Trial Locations (5)

15123

RECRUITING

Mitera Hospital, Athens

75015

TERMINATED

Paris Public Hospitals System; Necker Hospital for Sick Children, Paris

00165

RECRUITING

Bambino Gesu Children Hospital, Roma

BS28BJ

NOT_YET_RECRUITING

Bristol Royal Hospital for Children, Bristol

SE1 7EH

RECRUITING

King's College London, Rayne Institute, London

Sponsors

Lead Sponsor

GE Healthcare

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

GE Healthcare

INDUSTRY

NCT04604782 - A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | Biotech Hunter | Biotech Hunter